-
公开(公告)号:US20230338654A1
公开(公告)日:2023-10-26
申请号:US18139427
申请日:2023-04-26
Applicant: Dexcom, Inc.
Inventor: Stephen D. Patek , Matthew S. Gerber , Enrique Campos-Nanez , Thibault Gautier , Leah Ziegler
CPC classification number: A61M5/1723 , A61M5/16877 , A61M2202/0486 , A61M2205/50
Abstract: A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.
-
公开(公告)号:US20240249810A1
公开(公告)日:2024-07-25
申请号:US18417380
申请日:2024-01-19
Applicant: DEXCOM, INC.
Inventor: Stephen D. PATEK , Enrique Campos-Nanez , Matthew S. Gerber , Leah ZIEGLER , Thibault Pierre GAUTIER
CPC classification number: G16H20/17 , A61B5/14532 , A61B5/7275
Abstract: An insulin delivery rate converter includes a comparator and an insulin delivery supervisor. The comparator is configured to receive insulin data and glucose data and to determine a difference delta between (i) estimations of metabolic data and behavior data derived from the insulin data and blood glucose measurements; and (ii) estimations of metabolic data and behavior data derived from the insulin data without use of the blood glucose measurements. The insulin delivery supervisor is configured to modulate an insulin delivery rate based at least in part on the difference delta determined by the comparator.
-
公开(公告)号:US20240058532A1
公开(公告)日:2024-02-22
申请号:US18383133
申请日:2023-10-24
Applicant: Dexcom, Inc.
Inventor: Stephen D. Patek , Matthew S. Gerber , Enrique Campos-Nanez , Thibault Gautier , Leah Ziegler
CPC classification number: A61M5/1723 , A61M5/16877
Abstract: A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.
-
-